91 related articles for article (PubMed ID: 21311104)
1. HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis.
Buckton AJ; Harris RJ; Pillay D; Cane PA
Antivir Ther; 2011; 16(1):9-16. PubMed ID: 21311104
[TBL] [Abstract][Full Text] [Related]
2. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy.
Johnson JA; Li JF; Wei X; Lipscomb J; Irlbeck D; Craig C; Smith A; Bennett DE; Monsour M; Sandstrom P; Lanier ER; Heneine W
PLoS Med; 2008 Jul; 5(7):e158. PubMed ID: 18666824
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
[TBL] [Abstract][Full Text] [Related]
4. Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan.
Nishizawa M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
PLoS One; 2013; 8(12):e83150. PubMed ID: 24358257
[TBL] [Abstract][Full Text] [Related]
5. Minority HIV-1 resistant variants in recent infection and in patients who failed first-line antiretroviral therapy with no detectable resistance-associated mutations in Thailand.
Le Nguyen H; Pitakpolrat P; Sirivichayakul S; Delaugerre C; Ruxrungtham K
J Med Virol; 2012 May; 84(5):713-20. PubMed ID: 22431018
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Detection and Persistence of Minority Drug-Resistant Populations and Their Effect on Salvage Therapy.
Nishizawa M; Matsuda M; Hattori J; Shiino T; Matano T; Heneine W; Johnson JA; Sugiura W
PLoS One; 2015; 10(9):e0135941. PubMed ID: 26360259
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naïve patients.
Metzner KJ; Rauch P; Braun P; Knechten H; Ehret R; Korn K; Kaiser R; Sichtig N; Ranneberg B; van Lunzen J; Walter H
J Clin Virol; 2011 Feb; 50(2):156-61. PubMed ID: 21056001
[TBL] [Abstract][Full Text] [Related]
8. Multimethod Longitudinal HIV Drug Resistance Analysis in Antiretroviral-Therapy-Naive Patients.
Nanfack AJ; Redd AD; Bimela JS; Ncham G; Achem E; Banin AN; Kirkpatrick AR; Porcella SF; Agyingi LA; Meli J; Colizzi V; Nádas A; Gorny MK; Nyambi PN; Quinn TC; Duerr R
J Clin Microbiol; 2017 Sep; 55(9):2785-2800. PubMed ID: 28659324
[TBL] [Abstract][Full Text] [Related]
9. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance.
Buckton AJ; Prabhu D; Motamed C; Harris RJ; Hill C; Murphy G; Parry JV; Johnson JA; Lowndes CM; Gill N; Pillay D; Cane PA
HIV Med; 2011 Apr; 12(4):250-4. PubMed ID: 21371237
[TBL] [Abstract][Full Text] [Related]
10. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy.
Peuchant O; Thiébaut R; Capdepont S; Lavignolle-Aurillac V; Neau D; Morlat P; Dabis F; Fleury H; Masquelier B;
AIDS; 2008 Jul; 22(12):1417-23. PubMed ID: 18614864
[TBL] [Abstract][Full Text] [Related]
11. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
12. Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients.
Metzner KJ; Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Hirsch HH; Vernazza PL; Cavassini M; Calmy A; Bernasconi E; Weber R; Günthard HF;
AIDS; 2014 Sep; 28(15):2231-9. PubMed ID: 25036184
[TBL] [Abstract][Full Text] [Related]
13. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
[TBL] [Abstract][Full Text] [Related]
14. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
15. Presence of drug resistance mutations among drug-naive patients in Morocco.
Annaz HE; Recordon-Pinson P; Baba N; Sedrati O; Mrani S; Fleury H
AIDS Res Hum Retroviruses; 2011 Aug; 27(8):917-20. PubMed ID: 21087198
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
[TBL] [Abstract][Full Text] [Related]
17. [Study on genotypic resistance mutations to antiretroviral drugs on HIV strains of treated and treatment-naive HIV-1 infectious patients in Hubei province].
Wang XQ; Tong X; Tang H; Liu PP; Zhang W; Yang RG
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1112-5. PubMed ID: 18396668
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
[TBL] [Abstract][Full Text] [Related]
19. Drug-resistance mutations in antiretroviral-naïve patients with established HIV-1 infection in Mexico.
Escoto-Delgadillo M; Vázquez-Valls E; Ramírez-Rodríguez M; Corona-Nakamura A; Amaya-Tapia G; Quintero-Pérez N; Panduro-Cerda A; Torres-Mendoza BM
HIV Med; 2005 Nov; 6(6):403-9. PubMed ID: 16268822
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.
Yang WL; Kouyos R; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF;
J Infect Dis; 2015 Jul; 212(1):28-38. PubMed ID: 25576600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
